Drug intelligence / Profile preview

bli-1300

Development stage: Discontinued
Lead developer: Braintree Laboratories
Modality: Small Molecules
Administration: Topical

Overview

BLI-1300 is a topical small molecule ointment developed for the treatment of perianal Crohn's disease. Its precise mechanism of action is unknown, but it was investigated as a novel therapy for reducing perianal pain associated with active perianal Crohn's disease. The drug was developed by Braintree Laboratories and reached Phase 2 clinical trials before development was terminated[1][3][5]. No adverse events or FDA designations have been reported, and it has not received approval in any country[1].

Beyond the preview

Go deeper on bli-1300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bli-1300.

Explore the full profile